Page 11234..»

Category : Anti-Aging Medicine

New Anti-Aging Clinical Trial Begins. For $1 Million, You Can Be a Participant. – Livescience.com

An American biotech company has launched clinical trials in Colombia to test a new therapy designed to reverse the aging process, and in turn, treat age-related diseases, according to news reports.

But to steal a sip from this purported fountain of youth, participants in the trial must first fork over $1 million a fee that seems even more astronomical when you consider that most clinical trials are either free or provide participants with financial compensation, according to a report by OneZero, a Medium publication about tech and science.

The pricey trial is being run by Libella Gene Therapeutics, a Kansas-based company whose website proclaims that "the future is here." The company announced its intention to test its anti-aging remedies in Cartagena, Colombia, in 2018, and began recruiting for the trials in October of this year. Using a single-gene therapy, Libella aims to "prevent, delay, or even reverse" the general effects of aging, as well as treat diseases that emerge in old age, such as Alzheimer's, according to ClinicalTrials.gov.

In fact, in its own press release, the company boasted, without evidence, that its gene therapy "may be the world's first cure for Alzheimer's disease." The bold claim raises an obvious question: Will the treatment actually work?

Short answer: No one really knows, but the fact that Libella shipped its operation beyond the reach of the U.S. Food and Drug Administration (FDA) doesn't inspire confidence, experts told OneZero.

Related: 5 Reasons Not to Fear Getting Older

Unlike anti-aging face creams that soften the superficial signs of aging, the Libella therapy aims to reverse aging from the ground up, so to speak, starting at the level of our genes. Specifically, the gene therapy is intended to lengthen patients' telomeres structures that cap the tips of chromosomes and prevent the genetic material inside from fraying. Telomeres grow shorter each time a cell divides, and when the structures reach a critical length, cells either stop dividing or perish, according to Stanford Medicine.

The theory goes, if you rebuild the body's shortened telomeres, the process of aging might be thrown in reverse. This is not a new idea. Several studies in mice suggest that using gene therapy to lengthen telomeres can reverse certain signs of aging in the animals. A 2015 study from Stanford prompted similar effects in isolated human cells; the treatment lengthened cells' telomeres by fiddling with a close cousin of DNA, called RNA, which helps cells build proteins.

The Libella therapy aims to help cells rebuild telomeres by activating a gene in their DNA that would normally be switched "off." The gene, called TERT, contains instructions to build a protein called "telomerase," an enzyme that adds molecules to the end of telomeres and prevents the structures from shortening during cell replication, according to a 2010 report in the journal Biochemistry.

Libella's lead scientific officer, molecular biologist William Andrews, originally helped identify the human telomerase enzyme at the biotech firm Geron. Later, he licensed a gene therapy based on the finding to Libella, according to OneZero. "I can't say [telomere shortening is] the only cause of aging, but it plays a role in humans," Andrews told the publication.

Related: 8 Tips for Healthy Aging

Andrews' therapies will soon be put to the test in Colombia, where one 79-year-old will receive the anti-aging treatment in next month, according to OneZero. The anti-aging trial will include four more participants over age 45 and focus on verifying that the treatment is "safe and tolerable," meaning it does not harm patients or cause unacceptable side effects.

Two more trials will use the same therapy but aim to "prevent, delay, or even reverse the development" of Alzheimer's disease and critical limb ischemia, an age-related condition in which a person's arteries become severely obstructed. Participants in these trials must already be diagnosed with the disorders.

After treatment, participants in all three trials will remain in the clinic for 10 days for further monitoring, and then return at regular intervals for checkups over the following year.

Libella's gene therapy involves a one-time injection delivered through an IV; the Alzheimer's therapy uses the same formula but doctors inject the product into the patient's spinal fluid. Within the product, a modified virus carries the TERT gene into cells and injects the genetic material into their DNA. The modified viruses cannot transmit diseases to people, but in high enough doses, the germs could provoke a harmful immune response in the patient, according to a 2018 animal study. Libella representatives declined to say how high a dose their clinical trial participants will receive.

"All I can say is, it's a lot," Andrews told OneZero.

Potential side effects aside, the fact that the Libella treatment will be administered beyond the purview of the FDA is telling, according to one expert. Leigh Turner, a bioethicist at the University of Minnesota, told OneZero that "even though the company is based in the United States, they've managed to find a way to evade U.S. federal law by going to a jurisdiction where it's easier to engage in this activity."

The $1 million entry fee is also alarming, Turner said, given that most clinical trials don't charge patients anything to enter. Andrews told OneZero that the fee is justified because it costs the company hundreds of thousands of dollars to make enough product to treat just one person.

The appearance of the trials on ClinicalTrials.gov, an official registry maintained by the National Institutes of Health, does not boost their credibility, she added. The automated database can be easily manipulated and "can basically be used as a marketing platform," she said.

Other stakeholders in the telomere-lengthening business are concerned, too. Michael Fossel, founder and president of the biotech startup Telocyte, told OneZero that his company's own therapy is similar to the Libella treatment the difference is that Telocyte is seeking approval through the FDA. "We're afraid that something will go wrong [with the Libella trials], whether it's from a safety or efficacy standpoint," he said.

Related: Extending Life: 7 Ways to Live Past 100

But even in a best case scenario, wherein no patients come to harm, the Libella therapy still might not deliver any notable health benefits. Some research suggests that no link exists between telomere length and aging.

For instance, a study published this year examined more than 261,000 people between age 60 and 70, and found no correlation between participants' telomere lengths and their age-related health outcomes, including their overall cognitive function, muscular integrity and the age of their parents. Long telomeres were associated with a lowered risk of coronary heart disease as compared with short telomeres, but longer telomere length was also linked to a heightened risk of cancer.

"Telomere lengthening may offer little gain in laterlife health status" and lead to an increased risk of cancer, the authors noted.

It remains to be seen whether Libella has truly tapped the fountain of youth, but given the dubious nature of their clinical trials, potential participants may want to exercise caution before relocating to Colombia and shelling out $1 million for a chance to live longer.

Originally published on Live Science.

Read more here:

New Anti-Aging Clinical Trial Begins. For $1 Million, You Can Be a Participant. - Livescience.com

Recommendation and review posted by Alexandra Lee Anderson

Dr. Nathan S. Bryan is the First to Speak at the 27th Annual World Congress About Nitric Oxide’s Link to Mental Illness – P&T Community

LAS VEGAS, Dec. 12, 2019 /PRNewswire/ --On Friday Dec. 13, 2019, Dr. Nathan S. Bryan is the first to speak about the correlation between low nitric oxide levels and mental illness at the 27th Annual World Congress. With over 3,000 of his peers, Dr. Bryan will take center stage, speaking about the history, effects, causes and findings on nitric oxide, especially as it relates to mental health and neurological conditions.

Dr. Bryan has spent the past 20 years researching nitric oxide. His many seminal discoveries in the field of nitric oxide has led to dozens of issued U.S. and International Patents. He has published hundreds of peer-reviewed studies on nitric oxide and is considered an international expert on nitric oxide biochemistry and physiology.

Over 44 million American adults have a mental health condition. Since the release of the first State of Mental Health in America report (2015), there has only been a slight decrease in the number of adults who have a mental health condition (from 18.19% to 18.07%).

It is becoming increasingly clear that most if not all diseases are characterized or associated with perturbations in nitric oxide production/signaling. Loss of nitric oxide production is associated and even causal for most if not all chronic human diseases, including neurological disease. Therefore, restoring nitric oxide production may be one of the single most important therapeutic strategies for any health care practitioner. Therapeutics or strategies designed to restore normal nitric oxide homeostasis will have broad application and utility in human health and profoundly affect the health of our aging population. However, finding product technology, either drug therapy or nutritional and supplementation, is confusing and often fraught with products that do not work. Health care practitioners can no longer ignore nitric oxide in their patients. Patients cannot and will not heal without first restoring the production of nitric oxide. Development of nitric oxide-based therapeutics is and will continue to be a major focus of biotech, pharmaceutical and nutritional companies. Education of the public and health care practitioners is essential since nitric oxide is absolutely necessary for patient health and for healing the human body.

"Every dysfunctional or diseased tissue or organ in every human disease has a common denominator and that commonality is loss of regulation of blood flow to that tissue or organ due to the loss of nitric oxide production. This includes diseases such as Alzheimer's, ADHD, depression, erectile dysfunction, diabetes, heart disease. If you cannot get oxygen and nutrients to individual cells, these cells cannot perform and as a consequence they fail. In order to rescue these cells and make individual organs work better, we must first focus on restoring the production of nitric oxide. Without this, every other therapy will eventually fail. This is the missing link in treatment of every major health problem worldwide," says Dr. Bryan.

The 27th Annual World Congress delivers world-class education focused on integrative health: through the most recently emerging clinical research, newly discovered therapies, and future scientific advances. Considered to be the largest event in Anti-Aging Medicine, each year's conference features a combination of unique programming, a diverse audience, and a collaborative learning environment. With an agenda specifically engineered to maximize clinical education and sessions, and an Exhibit Hall featuring hundreds of companies spotlighting the latest products, devices, and services in the field, the World Congress allows attendees to learn the newest, most innovative protocols & practicesall of which can immediately be integrated into patient care. The event attracts thousands of healthcare practitioners and professionals from across the globe to redefine mission and transform the field of modern medicine through top-tier education: with the ultimate goal of enhancing and enriching the entire landscape of health.

View original content:http://www.prnewswire.com/news-releases/dr-nathan-s-bryan-is-the-first-to-speak-at-the-27th-annual-world-congress-about-nitric-oxides-link-to-mental-illness-300973558.html

SOURCE Dr. Nathan S. Bryan

Continue reading here:

Dr. Nathan S. Bryan is the First to Speak at the 27th Annual World Congress About Nitric Oxide's Link to Mental Illness - P&T Community

Recommendation and review posted by Alexandra Lee Anderson

This Is the Most Kris Jenner Gift of All Time – The Cut

Recommendation and review posted by Alexandra Lee Anderson

ChromaDex Launches Tru Niagen Pro 500, the Largest Serving of Patented Nicotinamide Riboside Available WorldwideTru Niagen Pro 500 to be distributed…

LOS ANGELES, Dec. 11, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today announced the launch of Tru Niagen Pro 500, the largest daily serving of its patented nicotinamide riboside (NR, or Niagen) ingredient in the world. The product will be available exclusively through licensed healthcare practitioners in the United States, launching this weekend at the American Academy for Anti-Aging Medicine (A4M) Annual Meeting in Las Vegas, NV.

This new product will allow practitioners to provide a unique product to their patients who want more energy and improved cellular health, says ChromaDex CEO Rob Fried.

ChromaDex maintains a growing network of healthcare practitioners who distribute Tru Niagen products to their patients and is also partnered with Natural Partners Fullscript for additional distribution.

We are pleased to launch this new product exclusively through the healthcare practitioner channel, says ChromaDex Chief Scientific Officer Dr. Matthew Roberts. This new product launch marks a major milestone in a year already characterized by several new significant scientific publications, human clinical data, and regulatory approvals around the world for ChromaDex.

Niagen is the only commercially available NR which has twice been successfully reviewed under U.S. Food & Drug Association's (FDA) new dietary ingredient (NDI) notification requirement and has also been successfully notified to the FDA as generally recognized as safe (GRAS). ChromaDex has also secured regulatory approvals on its patent-protected ingredient in Canada, the European Union, and Australia.

For additional information on the science supporting Tru Niagen, please visit http://www.truniagen.com.

About TRU NIAGEN:TRU NIAGEN is a branded dietary supplement brought to market by key nicotinamide riboside chloride innovator and patent holder, ChromaDex. NIAGEN nicotinamide riboside chloride (NR), also supplied by ChromaDex, is the sole active ingredient in TRU NIAGEN. Multiple clinical trials demonstrate NIAGEN is proven to boost NAD (nicotinamide adenine dinucleotide) levels, which decline with age. Only NIAGEN has twice been successfully reviewed under FDA's new dietary ingredient (NDI) notification program, and has also been successfully notified to the FDA as generally recognized as safe (GRAS).

About ChromaDex:ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN nicotinamide riboside chloride, sold directly to consumers as TRU NIAGEN, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN is helping the world AGE BETTER. ChromaDex maintains a website at http://www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Forward-Looking Statements:This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2018, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at http://www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

ChromaDex Media Contact:Alex Worsham, Senior Director of Global Corporate Communications310-388-6706 ext. 689alexw@chromadex.com

ChromaDex Investor Relations Contact:Brianna Gerber, Vice President of FP&A and Investor Relations949-419-0288 ext. 127briannag@chromadex.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f993967a-6441-4840-a4c7-c0f714c01374

Tru Niagen Pro 500

Largest daily serving of ChromaDex's patented NR Niagen

Link:

ChromaDex Launches Tru Niagen Pro 500, the Largest Serving of Patented Nicotinamide Riboside Available WorldwideTru Niagen Pro 500 to be distributed...

Recommendation and review posted by Alexandra Lee Anderson

Cutting Edge Exosome Regenerative Therapy Comes to Yelm’s AM Medical – ThurstonTalk

When embryonic Stem Cell therapy was first discovered in 1998, it changed the face of medicine. The idea of being able to regenerate and replace damaged cells seemed futuristic at the time, yet today such treatments are commonplace. Now, science has taken another quantum leap this time into the nano-sized world of exosomes, tiny bubbles that grow out of cell walls and contain much of the information contained within the cell including Growth factors, microRNA and messenger RNA. Mesenchymal stem cell (MSC) exosome therapy is currently one of the hottest trends in regenerative medicine, one that patients at AM Medical in Yelm can now experience.

Everyone has heard of stem cell therapy, but it turns out that its not the stem cells that are doing the work, says Dr. Ana Mihalcea, President of AM Medical. Its the exosomes that carry the information of regeneration. Infused stem cells, attach to blood vessel walls, and then give off exosomes.

Exosomes have several key differences from stem cells; they do not get removed from the circulation like stem cells, which are in the body for less than 72 hours before they get destroyed by the immune system; they do not produce a rejection reaction because they are not a cell and contain no DNA, and they pass the blood brain barrier, Mihalcea notes. In a study on stroke scientists fluorescently tagged exosomes, and the infused exosomes went exactly to the region where the stroke had occurred, she adds. The same was not true of stem cells as they do not cross the blood brain barrier.

As a result of their powerful cargo, exosomes can be used to address a multitude of conditions, including arthritis, autoimmune disorders, cardiovascular and neurogenerative diseases like Parkinsons and Alzheimers. Old cells can be reprogrammed by MSC exosomes as the target cells can transcribe the microRNA into functional proteins. Just like a virus, the exosome information of the young stem cells can infect the old cells with Youth, explains Mihalcea.

Spinal cord injuries are an area in which exosomes have produced dramatic results. Mihalcea cites the example of Dr. Douglas J. Spiels Interventional Pain Specialty Practice in NJ. Dr. Spiel has been able to rehabilitate spinal cord injuries with Exosome infusions into the spine and intravenously, she says. After several weeks, hes had patients regain muscle strength and sensation. These are prolonged, ongoing regenerative effects that continued to improve for months after the infusion.

When it comes to autoimmune diseases, inflammation plays a key role. Again, exosomes are able to reduce the problem by downregulating inflammation. TGF Beta 3 [Transforming growth factor beta-3] is the most important anti-inflammatory protein in the body and is abundant in MSC exosomes says Mihalcea. Many more Growth factors for blood vessel growth, neuronal and other tissue growth are present, allowing regenerative effects in all organ systems including skin wounds and burns.

The exosomes at AM Medical come from a laboratory in Florida that conducted pioneering research in the field. They come from perinatal mesenchymal stem cells and are scanned for any possible viruses to ensure their safety. Once harvested, the exosomes are concentrated so they can be infused in large doses.

For patients who qualify, the infusion process takes 10 to 15 minutes. Already, its been producing results for AM Medical patients. Weve had people with arthritis and chronic pain who had great responses, Mihalcea notes. There is an overall increase in wellbeing and sense of rejuvenation that is definitely noticeable.

Perhaps one of the largest sources of excitement over exosomes has to do with their anti-aging effects. Recently, ideas about the root causes of aging have been evolving, according to Mihalcea. Its been thought that aging occurs due to multiple different reasons like stem cell exhaustion, epigenetic changes, telomere shortening and others, she explains. It turns out that exosomes can modify almost all the hallmarks of aging. Theyre changing epigenetic expression to youthful function, and there are many potential applications. This is a new frontier in regenerative medicine that can help many people.

Learn more by watching Dr. Ana Mihalceas video on Exosomes The New Frontier Part 1: Longevity and Age reversal or reading further on the AM Medical website.

Sponsored

Read more:

Cutting Edge Exosome Regenerative Therapy Comes to Yelm's AM Medical - ThurstonTalk

Recommendation and review posted by Alexandra Lee Anderson

Liza Horvath, Senior Advocate: Age better with the right medical attention – Monterey Herald

Question: You usually write about legal concerns, but I would like your opinion on a medical issue. I am getting older but still feel like I am in relatively good health. Every now and then when I see my doctor, I might ask about achy knees or tell him that I am more tired than usual. He usually responds by saying that it is to be expected as we age or, worse yet, he tries to give me a prescription! I know things are changing in the medical world and I wish my doctor would take a more proactive approach to keeping me healthy rather than writing me a prescription to treat aches or pain. Am I unrealistic to think that I can age better if I have access to the right medical advice?

Answer: As a senior advocate, I am open to addressing all types of senior concerns and healthy aging is at the top of my list of interests. Thank you for the question! You are right to be dissatisfied if your doctor responds that aches and fatigue should be expected as we age. There are literally daily advances being made in the anti-aging field and gaining access to the best and most researched wellness practices is essential for all of us if we want to stay healthy for as long as possible. I believe we can all agree that spending our last 10 or 20 years chronically ill before dying is an expensive nightmare we should all strive to avoid.

Over the past 25 years, leading scientists and clinicians have been researching and developing ways to personalize medicine based on a patients specific needs. Research shows the critical influence that diet, nutrition, lifestyle choices and environmental toxins have on the development of chronic diseases such as diabetes, heart disease, Alzheimers and cancer. Anti-aging or functional medicine doctors recognize the importance of establishing a patient-empowered health care system centered on prevention, early intervention of disease and optimal wellness throughout life rather than focusing on post-diagnosis, pharmaceutical-based care later in life when chronic illnesses may have already gained a foothold.

The Institute of Functional Medicine is a global organization seeking to advance Functional Medicine by partnering with academic medical centers, hospitals, universities, technology companies and our everyday doctors. You can find a list of functional practitioners at their website: IMF.org. David Sinclair, Ph.D., a professor of genetics at Harvard Medical School, has been researching aging for more than 20 years and recently released a book, Lifespan: Why We Age and Why We Dont Have To. Sinclair proposes that aging is a disease and, as such, is treatable and preventable. Also, self-proclaimed biohacker, Dave Asprey, recently released Superhuman: The Bulletproof Plan to Age Backward and Maybe Even Live Forever. Aspreys book is an easier read on the topic of anti-aging but, both books pave the way toward a new way to view aging.

We are right to question our doctors advice if we feel it is not addressing the problem and only treating symptoms. Our health is our greatest asset just ask anyone who is no longer healthy! Keep researching, reading, learning and be open to the possibility that through exercise, correct nutrition and personalized medicine it may be possible to stay healthy much longer.

Liza Horvath has over 30 years experience in the estate planning and trust fields and is a Licensed Professional Fiduciary. Liza currently serves as president of Monterey Trust Management. This is not intended to be legal or tax advice. If you have a question, call (831)646-5262 or email liza@montereytrust.com

See the rest here:

Liza Horvath, Senior Advocate: Age better with the right medical attention - Monterey Herald

Recommendation and review posted by Alexandra Lee Anderson

Anti-Aging Medicine Market : Future Innovation Strategies, Growth & Profit Analysis, Forecast by 2018 – 2026 – The Market Expedition

An exhaustive study report on the Anti-Aging Medicine Market published by Persistence Market Research offers an in-depth understanding of the critical aspects that are expected to propel the growth of the Anti-Aging Medicine Market in the foreseeable future. Furthermore, by analyzing the data enclosed in the report, leading investors, stakeholders and upcoming market players can devise strategic methodologies to gather momentum and enhance their global footprint in the current Anti-Aging Medicine Market landscape.

As per the critical nuances of the study, the Anti-Aging Medicine market is poised to grow at a CAGR of ~XX% and attain a value of ~US$XX by the end of 2029. Prevailing and future prospects of the Anti-Aging Medicine Market gives readers a sinuous understanding and detailed market intelligence of the Anti-Aging Medicine Market landscape.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) athttps://www.persistencemarketresearch.co/samples/26233

Important Aspects Related to the Anti-Aging Medicine Market Included in the Report

The report answers the following questions related to the Anti-Aging Medicine Market:

Get Access To TOC Covering 200+ Topics athttps://www.persistencemarketresearch.co/toc/26233

key players in the region.

Some of the players operating in the global anti-aging medicine market are Pfizer, Evolution GmbH, Himalaya Global Holdings Ltd., Cipla Limited, Mylan Laboratories, Novartis, Merck Group, Vitabiotics, William Ransom & Son Holdings Plc, Uni-Vite Healthcare and Health Made Easy Limited amongst others.

The report covers exhaustive analysis on:

Regional Analysis:

Report Highlights:

In order to get a strategic overview of the market,Access Research Methodology Prepared By Experts athttps://www.persistencemarketresearch.co/methodology/26233

Why are PMRs Analytical Insights the Best?

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:

Persistence Market Research305 Broadway, 7th FloorNew York City, NY 10007United StatesPh.no. +1-646-568-7751

Read more:

Anti-Aging Medicine Market : Future Innovation Strategies, Growth & Profit Analysis, Forecast by 2018 - 2026 - The Market Expedition

Recommendation and review posted by Alexandra Lee Anderson

Secret Behind Metformin’s Weight Loss and Anti-Aging Benefits Revealed – SciTechDaily

Researchers at McMaster University have unlocked one of the secrets behind the many benefits of metformin.

One of the most widely used medications in the world, metformin is commonly prescribed for Type 2 diabetes. However, in addition to its effects on lowering blood sugar, in preclinical models, metformin shows benefits on aging and a number of diverse diseases such as cognitive disorders, cancer and cardiovascular disease.

One question researchers have been asking is how this is being achieved.

A multi-year study led by a collaboration of McMasters basic science and clinical researchers has found that metformin induces the expression and secretion of a protein called growth differentiating factor 15, or GDF15.

The results were published today (December 9, 2019) in Nature Metabolism.

Hertzel Gerstein, left, professor of medicine; Emily Day, PhD medical sciences student, and Gregory Steinberg, professor of medicine at McMaster University. Credit: McMaster University

Studies over the past two decades have shown that metformin does more than lower glucose, but we havent understood why, said Gregory Steinberg, senior author and professor of medicine at McMaster. He is also co-director of the Centre for Metabolism, Obesity and Diabetes Research at McMaster.

We went into this study with the idea that metformin might communicate with other tissues in the body by causing the secretion of a protein from the liver. We were totally surprised when we found out that metformin caused the secretion of GDF15, a protein which is known to suppress appetite.

The study team took that knowledge and applied it to mice to better understand the science behind the outcome. Scientists deleted the gene that makes GDF15 in mice, then treated them with metformin. The results showed that mice without GDF15 did not eat less or lose weight, despite being administered metformin, establishing GDF15 as the connection between metformin and weight loss.

The researchers say the findings open a number of avenues of research. There are currently over 1,500 registered clinical trials to test the effects of metformin in aging and different diseases.

The possibility that GDF15 has a role in multiple beneficial effects of metformin treatment on aging or diseases like cancer needs to be studied, Steinberg said.

Reference: Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss by Emily A. Day, Rebecca J. Ford, Brennan K. Smith, Pedrum Mohammadi-Shemirani, Marisa R. Morrow, Robert M. Gutgesell, Rachel Lu, Amogelang R. Raphenya, Mostafa Kabiri, Andrew G. McArthur, Natalia McInnes, Sibylle Hess, Guillaume Par, Hertzel C. Gerstein and Gregory R. Steinberg, 9 December 2019, Nature Metabolism.DOI: 10.1038/s42255-019-0146-4

The study was funded by the Canadian Institutes of Health Research (CIHR) and Diabetes Canada.

Go here to read the rest:

Secret Behind Metformin's Weight Loss and Anti-Aging Benefits Revealed - SciTechDaily

Recommendation and review posted by Alexandra Lee Anderson

Why We Aren’t Anti-Aging, We Are Pro-Healthy Aging – mindbodygreen.com

For the first time, we are starting to see research that targets aging as a health condition in and of itself. Finding ways to regulate those "longevity gene" pathways referenced by Lipman above (specifically the mTOR, AMPK, and sirtuins) is central to scientists' work in identifying lifestyle habits, nutritional compounds, and future drugs that could slow and even treat (yes, treat) aging.*

As Sinclair views it, aging is most definitely a disease, and the FDA classifying it as such will help the field move forward even faster, allowing for more research and development of drugs to target processes thatlead to age-related disease. "The definition of a disease is that over time you lose function, you become decrepit, disabled, and eventually, if it's a bad disease, you die from it," says Sinclair. "That sounds a lot like aging, right? If you go to the medical dictionary, the only difference between aging and a disease is that a disease affects less than half the populationand that 50% cutoff is completely arbitrary."

How likely is that to happen? In 2018, the World Health Organization classified aging as a disease and added it to the International Classifications of Diseases system. And right now, scientists at the Albert Einstein College of Medicine are examining the anti-aging effects of metformin in the Targeting Aging With Metformin (TAME) study. If researchers can show significant benefits of metformin in delaying problems such as cancer, dementia, stroke, and heart attacks, the FDA may consider classifying aging as a treatable condition.

But why study metformin? This widely prescribed diabetes drug, derived from compounds in the French lilac plant, has been noted for its benefits beyond diabetesand Sinclair predicts it will be the first drug prescribed specifically to treat aging. Turns out, "metformin had a protective effect against cancer, heart disease, and frailty in patients taking the drug for long-term diabetes treatment," says Sinclair. "Which sounds a lot like a molecule that can slow aging." Animal studies have also confirmed that metformin can improve life span, and, more importantly, health span in mice. And, in a first-of-its-kind study in humans published in September 2019, researchers were actually able to take 2.5 years off participants' biological clock using a combination of metformin, dehydroepiandrosterone (DHEA), and growth hormone.

Experts believe metformin may activate similar pathways as caloric restriction to stimulate autophagyor cellular cleaning. This cellular upkeep is believed to be a key factor in extending health span. "It's a relatively safe AMPK pathway activator, and that's thought to mimic the effects of fasting and exercising," says Sinclair, who takes metformin daily as part of his healthy aging regimen.

Excerpt from:

Why We Aren't Anti-Aging, We Are Pro-Healthy Aging - mindbodygreen.com

Recommendation and review posted by Alexandra Lee Anderson

Ederra Bella Plastic Surgery and Medical Spa in Johns Creek, Georgia, is Now Offering the Innovative CoolSculpting Procedure for Patients – Yahoo…

Top Atlanta area plastic surgeon, Dr. Myla Bennett, is excited to offer CoolSculpting at her luxurious medical spa facility.

JOHNS CREEK, Ga., Dec. 11, 2019 /PRNewswire-PRWeb/ -- Dr. Myla Bennett is a highly-skilled plastic surgeon, skincare expert and founder of Ederra Bella Plastic Surgery and Medical Spa in Johns Creek, Georgia. In an effort to continue to provide advanced treatment options for patients, Ederra Bella is now offering the CoolSculpting procedure. It is the only FDA-cleared fat reduction technology to use controlled cooling to safely target fat cells in areas including the abdomen, thigh and flank areas. Once the targeted fat cells are eliminated from the body, they are gone for good. More than a million CoolSculpting procedures have been safely administered worldwide with proven results. A CoolSculpting session requires no needles, surgery or downtime, which makes it a great alternative to liposuction. It is ideal for candidates who have hard-to-lose-fat in areas that are resistant to exercise and diet.

"We are excited to offer this treatment option to our patients at Ederra Bella. CoolSculpting has shown significant results in removing fat, without the potential risks and downtime of invasive procedures. I have found it to be extremely effective, especially on resistant localized areas, such as back fat, love handles and isolated belly fat. The CoolSculpting procedure is quite comfortable, and patients are highly satisfied with the aesthetic outcomes," says Dr. Myla Bennett

The number of treatments required for the desired results can vary. Dr. Myla Bennett will develop a customized CoolSculpting treatment plan based on an individual's needs, the areas focused on and budget. Treatment time typically lasts between one to two hours, and patients can have additional sessions for more pronounced effects. Ederra Bella Plastic Surgery and Medical Spa's location creates a relaxed setting for patients to receive cosmetic surgical and medical spa treatments, including CoolSculpting. Dr. Myla Bennett and her team offer a wide range of procedures, such as breast augmentation, tummy tucks, liposuction, dermal fillers and injectables, anti-aging treatments and more.

More about Myla Bennett, M.D.

Dr. Myla Bennett is a well-respected, board-certified plastic surgeon and skincare expert. She earned her medical degree from the Ohio State University of Medicine and completed her plastic and reconstructive surgery and general surgery residencies there as well. She then continued her training at the university with admission to the fellowship program. With several years of experience in the industry, Dr. Myla Bennett uses her expertise to perform plastic surgery procedures and other treatments with the goal of enhancing patients' natural beauty.

For more information on CoolSculpting and other services available at Ederra Bella Plastic Surgery and Medical Spa, please call (678)-325-0006 or visit http://www.ederrabella.com.

SOURCE Ederra Bella

Original post:

Ederra Bella Plastic Surgery and Medical Spa in Johns Creek, Georgia, is Now Offering the Innovative CoolSculpting Procedure for Patients - Yahoo...

Recommendation and review posted by Alexandra Lee Anderson


Page 11234..»